A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Like many GLP-1 medications approved for diabetes, however, weight loss is a side effect of Rybelsus. “Data has shown modest ...

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new ...

But -- finally -- Pfizer is getting into the obesity drug game. This past week, the company announced it will acquire Metsera ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much ...

Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the ...

“Semaglutide hits one receptor. It was the first one that came out,” Dr. Howe said. “Tirzepatide hits two receptors, and studies show that with tirzepatide, you get about a 32% weight loss compared to ...

Oral Ozempic alternative Orforglipron inspired the biggest biotech investment in Texas history, in Generation Park.

Pfizer is expediting its efforts to delve into the growing obesity treatment field with a nearly $5 billion acquisition. The ...